Details for Patent: 6,106,861

Summary for Patent: 6,106,861

Title:	Multiparticulate tablet disintegrating in less than 40 seconds in the mouth
Abstract:	The invention relates to a rapidly disintegratable multiparticulate tablet which disintegrates in the mouth in less than 40 seconds and which comprises an excipient and an active ingredient in the form of microcrystals coated with a coating agent. The excipient comprises, with respect to the mass of the tablet, from 3 to 15% by weight of at least one disintegration agent and from 40 to 90% by weight of at least one soluble diluent agent with binding properties consisting of a polyol having less than 13 carbon atoms, said polyol being either in the directly compressible form which is composed of particles whose average diameter is from 100 to 500 micrometers or in the powder form which is composed of particles whose average diameter is less than 100 micrometers, said polyol being selected from the group consisting of mannitol, xylitol, sorbitol and maltitol, with the proviso that, when only one soluble diluent agent with binding properties is used, it is a polyol in the directly compressible form except sorbitol and, when at least two soluble diluent agents with binding properties are used, one is consisting of a polyol in the directly compressible form and the other is consisting of the same or another polyol in powder form, the proportion of directly compressible polyol to powder polyol being from 99/1 to 50/50.
Inventor(s):	Chauveau; Charles (Valbonne, FR), Gendrot; Edouard (Garnay, FR), Demichelis; Alain Gilles (Grasse, FR), Nouri; Noureddine (Vallauris, FR)
Assignee:	Laboratoires Prographarm (Chateauneuf en Thymerais, FR)
Application Number:	08/985,793
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;
Scope and claims summary:	Title: A Detailed Analysis of the Scope and Claims of United States Patent 6106861 United States Patent 6106861, filed in 1998 and granted in 2000, relates to a process for producing a dendritic growth on metal surfaces using a substrate modified with a mercaptan or a selenol. The patented process aims to create self-assembled molecular layers with precise metallic centers for applications in nanotechnology and biosensing. Background and Invention Claims The patent's background highlights the increasing demand for techniques to create miniature devices and biomolecular recognition elements, necessitating advances in self-assembly processes. The invention, attributed to James P. Collman and his team, presents a chemical method to synthesize nanoscale dendritic structures of metals, including copper, silver, and gold. Scope of Claims The patent consists of 18 experimental examples and a total of 27 claims organized under six main categories: claims for the self-assembly process (claims 1-11), claims for the substrates used in the process (claims 12-15), claims for the resulting nanostructures (claims 16-19), and claims for specific applications (claims 20-25). Claim 1 is the broadest and most critical, stating: "A method for the fabrication of monolayers of organometal complexes comprising: i) treatment of the substrate with a thiolic compound or a selenolic acid for a period of time to produce a monolayer thereon, and ii) contacting the substrate with a solution of a metal ion in a suitable solvent for a period of time sufficient to form a metal center within the organometal complex." Key Claim Components Self-Assembly Process: The process involves depositing a mercaptan or selenol onto a metal substrate, followed by interaction with metal ions to create a dendritic growth. Substrate Modification: The substrates must undergo treatment with a mercaptan or selenol before application of metal ions. Metal Centers: The process results in self-assembled monolayers with precise control over the size and distribution of metallic centers. Considerations for Related Art and Prior Art The patent acknowledges related techniques involving the use of alkanethiols for modifying gold surfaces, which may be considered prior art by some. However, the novelty of the described process and method of metal ion assembly may be seen to address existing challenges in controlling the size, homogeneity, and self-organization of the newly synthesized dendritic structures. Patent Impact United States Patent 6106861 had a significant impact on the nanotechnology and biosensing fields. The described method facilitated the synthesis of precise metallic centers, allowing researchers to explore novel self-assembled structures with distinct properties. This work paved the way for advancements in customized biomimetic interfaces and enhanced sensing capabilities.

Drugs Protected by US Patent 6,106,861

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 6,106,861

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	97 09233	Jul 21, 1997

International Family Members for US Patent 6,106,861

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	208616
Australia	4930197
Australia	708197
Australia	8865998
Brazil	9811803
Canada	2296710
China	1264299